The authors of that study also proposed to use of FGFR3 inhibitors in combination with PD-1/PD-L1 inhibitors as a targeted therapeutic strategy to regulate the T-cell-depleted phenotype of UTUC [36]. This evidence concerns the gene FGFR3 and renal pelvis/ureter urothelial carcinoma.